Jinhua Xu

Jinhua Xu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JXJinhua Xu
Jinhua Xu
JPJeni Prosperi
Jeni Prosperi
NCNoura Choudhury
Noura Choudhury
OOOlufunmilayo I. Olopade
Olufunmilayo I. Olopade
KGKathleen H. Goss
Kathleen H. Goss
Our previous data illustrated that activation of the canonical Wnt signaling pathway was enriched in triple-negative breast cancer and associated with reduced overall survival in all patients. To determine whether Wnt signaling may be a promising therapeutic target for triple-negative breast cancer, we investigated whether β-catenin was necessary for tumorigenic behaviors in vivo and in vitro. β-catenin expression level was significantly reduced in two human triple-negative breast cancer cell lines, MDA-MB-231 and HCC38, using lentiviral delivery of β-catenin-specific small hairpin RNAs (shRNAs). Upon implantation of the cells in the mammary fat pad of immunocompromised mice, we found that β-catenin shRNA HCC38 cells formed markedly smaller tumors than control cells and grew much more slowly. In in vitro assays, β-catenin silencing significantly reduced the percentage of Aldefluor-positive cells, a read-out of the stem-like cell population, as well as the expression of stem cell-related target genes including Bmi-1 and c-Myc. β-catenin-knockdown cells were also significantly impaired in their ability to migrate in wound-filling assays and form anchorage-independent colonies in soft agar. β-catenin-knockdown cells were more sensitive to chemotherapeutic agents doxorubicin and cisplatin. Collectively, these data suggest that β-catenin is required for triple-negative breast cancer development by controlling numerous tumor-associated properties, such as migration, stemness, anchorage-independent growth and chemosensitivity.

8 February 2015 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
JXJinhua Xu
Jinhua Xu
YCYinghua Chen
Yinghua Chen
DHDezheng Huo
Dezheng Huo
AKAndrey Khramtsov
Andrey Khramtsov
GKGalina Khramtsova
Galina Khramtsova
OOOlufunmilayo I. Olopade
Olufunmilayo I. Olopade

13 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
LFLimei Fan
Limei Fan
MTMuyou Tian
Muyou Tian
YLYunyi Liu
Yunyi Liu
YDYing Deng
Ying Deng
ZLzhengkai Liao
zhengkai Liao
JXJinhua Xu
Jinhua Xu
Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells

27 July 2023 in Oncology Reports
Verified
Journal Article
Open access
PDF file
ZLZixin Liu
Zixin Liu
LFLimei Fan
Limei Fan
DNDongqin Niu
Dongqin Niu
MCMing Chen
Ming Chen
WZWeiran Zhang
Weiran Zhang
DWDong Wang
Dong Wang
Oxaliplatin (Oxa) is one of the most effective chemotherapeutic drugs used in the treatment of colorectal cancer (CRC). However, the use of this drug is associated with severe side‑effects and patients eventually develop resistance to Oxa. In recent years, copper complexes have been extensively investigated as substitutes for platinum‑based drugs. Therefore, a number of copper complexes have also been developed for cancer therapy, such as copper (II) complex of salicylate phenanthroline [Cu(sal)(phen)]. In the present study, the antitumor activity and the related molecular mechanisms of Cu(sal)(phen) were examined in CRC cells. As compared with the chemotherapeutic drug, Oxa, Cu(sal)(phen) was more effective in inducing apoptosis and reactive oxygen species (ROS) production, and in decreasing mitochondrial membrane potential in the CRC cell lines, HCT116 and SW480. In addition, the expression of the apoptosis‑related proteins, Bcl‑2 and survivin, and those of the upstream regulators, p‑JAK2 and p‑STAT5, were significantly decreased in the two cell lines following treatment with Cu(sal)(phen). Furthermore, the efficacy of the complex against CRC was found to be excellent in an animal model. The results of immunohistochemical analysis revealed that the expression levels of Bcl‑2, survivin and Ki‑67 in tumor tissues were decreased following Cu(sal)(phen) treatment. The antitumor mechanisms underlying Cu(Sal)(phen) treatment were the induction of ROS generation, the inhibition of the JAK2/STAT5 signaling pathway and the downregulation of the expression of anti‑apoptotic proteins, such as Bcl‑2 and survivin. On the whole, the findings of the present study indicated that Cu(sal)(phen) effectively inhibited the viability and proliferation of HCT116 and SW480 CRC cells; in the future, the authors aim to conduct further experiments in future studies to provide more evidence that supports the development of Cu(sal)(phen) as a therapeutic agent for CRC.

16 March 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HCHeng Chen
Heng Chen
DWDong Wang
Dong Wang
LFLimei Fan
Limei Fan
ZLZixin Liu
Zixin Liu
WZWeiran Zhang
Weiran Zhang
YLYunyi Liu
Yunyi Liu
The zinc complex of 3,5-di-tert-butyl salicylate (Zn{[CH3)3C]2Sal}22−) is a zinc ion chelate of salicylate. In this study, we found that this compound inhibits viability, invasion, and migration and induces apoptosis in triple-negative breast cancer 4T1 cells. RNA-seq showed that the expression of 17 genes was upregulated and 26 genes were downregulated significantly by Zn{[CH3)3C]2Sal}22− treatment. Further GO and KEGG analysis showed that the activity of Zn{[CH3)3C]2Sal}22− against triple-negative breast cancer cells may be involved in the JAK-STAT3, HIF-1, and TNF signaling pathways. The expression of key genes was verified by RT–PCR. The phosphorylation of STAT3 and its upstream SRC decreased drastically upon Zn{[CH3)3C]2Sal}22− treatment, as demonstrated by western blot. Our results indicate that Zn{[CH3)3C]2Sal}22− inhibits the activity of TNBC cells by downregulating the STAT3 signaling through the SRC pathway.